Lipoprotein(a) and ischemic heart disease-A causal association? A review

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 15-23

  Kamstrup, Pia R ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Causality; Epidemiology; Genetics; Ischemic heart disease; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; GENETIC EPIDEMIOLOGY; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; MORBIDITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; ANIMAL; BLOOD; GENETICS; HEART MUSCLE ISCHEMIA; MOLECULAR EPIDEMIOLOGY;

ANIMALS; HUMANS; LIPOPROTEIN(A); MOLECULAR EPIDEMIOLOGY; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 77954312278     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.036     Document Type: Review

References (111)

1. Utermann G. Lipoprotein (a). The metabolic and molecular bases of inherited disease 2006, 2753-2787. Mc-Graw-Hill, Medical Publishing Division. 2001 ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Kronenberg F., Trenkwalder E., Lingenhel A., et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997, 38:1755-1763.
3. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
4. Kraft H.G., Kochl S., Menzel H.J., Sandholzer C., Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992, 90:220-230.
5. Lackner C., Cohen J.C., Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993, 2:933-940.
6. Haibach C., Kraft H.G., Kochl S., Abe A., Utermann G. The number of kringle IV repeats 3-10 is invariable in the human apo(a) gene. Gene 1998, 208:253-258.
7. Rothman K.J., Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005, 95(Suppl 1):S144-S150.
8. Clayton D., McKeigue P.M. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001, 358:1356-1360.
9. Katan M.B. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986, 1:507-508.
10. Nitsch D., Molokhia M., Smeeth L., DeStavola B.L., Whittaker J.C., Leon D.A. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol 2006, 163:397-403.
11. Smith G.D., Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 2003, 32:1-22.
12. Smith G.D., Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004, 33:30-42.
13. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963, 59:369-382.
14. Alfthan G., Pekkanen J., Jauhiainen M., et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994, 106:9-19.
15. Cantin B., Gagnon F., Moorjani S., et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998, 31:519-525.
16. Ridker P.M., Hennekens C.H., Stampfer M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993, 270:2195-2199.
17. Kronenberg F., Trenkwalder E., Dieplinger H., Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996, 16:1568-1572.
18. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995, 41:246-255.
19. Marcovina S.M., Koschinsky M.L., Albers J.J., Skarlatos S. Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003, 49:1785-1796.
20. Tate J.R., Rifai N., Berg K., et al. International federation of clinical chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 1998, 44:1629-1640.
21. Rifai N., Ma J., Sacks F.M., et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians' health study. Clin Chem 2004, 50:1364-1371.
22. Danik J.S., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363-1370.
23. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., Haddow J.E. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998, 44:2301-2306.
24. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease-meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
25. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
26. Ariyo A.A., Thach C., Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003, 349:2108-2115.
27. Kamstrup P.R., Benn M., Tybjærg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117:176-184.
28. Luc G., Bard J.M., Arveiler D., et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis 2002, 163:377-384.
29. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 2001, 104:1108-1113.
30. von Eckardstein A., Schulte H., Cullen P., Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001, 37:434-439.
31. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007, 27:1788-1795.
32. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57.
33. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006, 47:2219-2228.
34. Kraft H.G., Lingenhel A., Pang R.W., et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian. Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 1996, 4:74-87.
35. Nielsen L.B., Grønholdt M.L., Schroeder T.V., Stender S., Nordestgaard B.G. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997, 17:905-911.
36. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989, 9:579-592.
37. Baldo G., Giunco S., Kontothanassis D., Baiocchi M.R., Valerio A., Frego M. Different apoprotein(a) isoform proportions in serum and carotid plaque. Atherosclerosis 2007, 193:177-185.
38. Deb A., Caplice N.M. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 2004, 27:258-264.
39. Allen S., Khan S., Tam S., Koschinsky M., Taylor P., Yacoub M. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J 1998, 12:1765-1776.
40. Poon M., Zhang X., Dunsky K.G., Taubman M.B., Harpel P.C. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997, 96:2514-2519.
41. Haberland M.E., Fless G.M., Scanu A.M., Fogelman A.M. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992, 267:4143-4151.
42. Klezovitch O., Edelstein C., Scanu A.M. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 2001, 276:46864-46869.
43. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993, 260:1655-1658.
44. Grainger D.J., Kemp P.R., Liu A.C., Lawn R.M., Metcalfe J.C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370:460-462.
45. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003, 278:52841-52847.
46. Navab M., Hama S.Y., Reddy S.T., et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002, 13:363-372.
47. Marcovina S.M., Koschinsky M.L. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003, 14:361-366.
48. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989, 339:303-305.
49. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989, 339:301-303.
50. Loscalzo J., Weinfeld M., Fless G.M., Scanu A.M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990, 10:240-245.
51. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L., Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991, 266:2459-2465.
52. Caplice N.M., Panetta C., Peterson T.E., et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001, 98:2980-2987.
53. Nielsen L.B., Nordestgaard B.G., Stender S., Niendorf A., Kjeldsen K. Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1492-1502.
54. Nielsen L.B., Juul K., Nordestgaard B.G. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 1998, 18:641-649.
55. Nielsen L.B., Stender S., Jauhiainen M., Nordestgaard B.G. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest 1996, 98:563-571.
56. Nielsen L.B., Stender S., Kjeldsen K., Nordestgaard B.G. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res 1996, 78:615-626.
57. Boffa M.B., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004, 37:333-343.
58. Lawn R.M., Wade D.P., Hammer R.E., Chiesa G., Verstuyft J.G., Rubin E.M. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992, 360:670-672.
59. Devlin C.M., Lee S.J., Kuriakose G., et al. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol 2005, 25:1704-1710.
60. Fan J., Shimoyamada H., Sun H., Marcovina S., Honda K., Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001, 21:88-94.
61. Sun H., Unoki H., Wang X., et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem 2002, 277:47486-47492.
62. Biemond B.J., Friederich P.W., Koschinsky M.L., et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997, 96:1612-1615.
63. Palabrica T.M., Liu A.C., Aronovitz M.J., Furie B., Lawn R.M., Furie B.C. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995, 1:256-259.
64. Jenner J.L., Ordovas J.M., Lamonfava S., et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels-the Framingham offspring study. Circulation 1993, 87:1135-1141.
65. Kronenberg F. Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. Expert Rev Cardiovasc Ther 2004, 2:729-743.
66. Lingenhel A., Kraft H.G., Kotze M., et al. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998, 6:50-60.
67. Seed M., Hoppichler F., Reaveley D., et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990, 322:1494-1499.
68. Rader D.J., Mann W.A., Cain W., et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995, 95:1403-1408.
69. Frischmann M.E., Kronenberg F., Trenkwalder E., et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007, 71:1036-1043.
70. Maher V.M., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.Q., Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771-1774.
71. Jones G.T., van Rij A.M., Cole J., et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem 2007, 53:679-685.
72. Shlipak M.G., Simon J.A., Vittinghoff E., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000, 283:1845-1852.
73. Danik J.S., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008, 52:124-131.
74. Liu L., Zhao S.P., Cheng Y.C., Li Y.L. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003, 49:1347-1352.
75. Akaike M., Azuma H., Kagawa A., et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48:1454-1459.
76. Merki E., Graham M.J., Mullick A.E., et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008, 118:743-753.
77. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(A) in hyperlipemic subjects treated with nicotinic-acid. J Intern Med 1989, 226:271-276.
78. Rader D.J., Hoeg J.M., Brewer H.B. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994, 120:1012-1025.
79. Scanu A.M., Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008, 101:44B-47B.
80. Kamstrup P.R., Tybjærg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
81. Rosby O., Berg K. LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J Intern Med 2000, 247:139-152.
82. Sandholzer C., Hallman D.M., Saha N., et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991, 86:607-614.
83. Brunner C., Lobentanz E.M., Petho-Schramm A., et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996, 271:32403-32410.
84. Amemiya H., Arinami T., Kikuchi S., et al. Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis 1996, 123:181-191.
85. Brazier L., Tiret L., Luc G., et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM study. Atherosclerosis 1999, 144:323-333.
86. Gazzaruso C., Garzaniti A., Buscaglia P., et al. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 1999, 33:157-163.
87. Holmer S.R., Hengstenberg C., Kraft H.G., et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003, 107:696-701.
88. Kark J.D., Sandholzer C., Friedlander Y., Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993, 98:139-151.
89. Klausen I.C., Sjol A., Hansen P.S., et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 1997, 132:77-84.
90. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619-2624.
91. Sandholzer C., Saha N., Kark J.D., et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992, 12:1214-1226.
92. Sandholzer C., Boerwinkle E., Saha N., Tong M.C., Utermann G. Apolipoprotein(a) phenotypes. Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992, 89:1040-1046.
93. Wild S.H., Fortmann S.P., Marcovina S.M. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997, 17:239-245.
94. Boes E., Coassin S., Kollerits B., Heid I.M., Kronenberg F. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol 2009, 44:136-160.
95. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999, 100:1154-1160.
96. Kronenberg F., Neyer U., Lhotta K., et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999, 10:1027-1036.
97. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005, 16:1794-1802.
98. Gazzaruso C., Bruno R., Pujia A., et al. Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. Int J Cardiol 2006, 108:354-358.
99. Chimienti G., Lamanuzzi B.L., Nardulli M., et al. APO(a) variants and lipoprotein(a) in men with or without myocardial infarction. Exp Mol Pathol 2002, 73:28-34.
100. Geethanjali F.S., Luthra K., Lingenhel A., et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003, 169:121-130.
101. Kraft H.G., Lingenhel A., Kochl S., et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996, 16:713-719.
102. Kraft H.G., Windegger M., Menzel H.J., Utermann G. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998, 7:257-264.
103. Trommsdorff M., Kochl S., Lingenhel A., et al. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995, 96:150-157.
104. Kamstrup P.R., Tybjærg-Hansen A., Steffensen R., Nordestgaard B.G. Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2008, 93:3769-3776.
105. Sun L., Li Z., Zhang H., et al. Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese: a multicenter case-control study in China. Stroke 2003, 34:1617-1622.
106. Valenti K., Aveynier E., Leaute S., Laporte F., Hadjian A.J. Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis 1999, 147:17-24.
107. Bopp S., Kochl S., Acquati F., et al. Ten allelic apolipoprotein[a] 5' flanking fragments exhibit comparable promoter activities in HepG2 cells. J Lipid Res 1995, 36:1721-1728.
108. Luke M.M., Kane J.P., Liu D.M., et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2030-2036.
109. Shiffman D., Kane J.P., Louie J.Z., et al. Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction. PLoS One 2008, 3:e2895.
110. Shiffman D., O'Meara E.S., Bare L.A., et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008, 28:173-179.
111. Tregouet D.A., Konig I.R., Erdmann J., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009, 41:283-285.